Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. LLY
LLY logo

LLY

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

LLY News

Eli Lilly's GLP-1 Drug Sales Surge Remarkably

16h agoYahoo Finance

Eli Lilly's GLP-1 Drug Sales Surge

16h agoFool

Eli Lilly's GLP-1 Drug Sales Surge Amid Competition

16h agoNASDAQ.COM

Investment Opportunities in GLP-1 Drugs in Healthcare

1d agoFool

Eli Lilly Reshapes Weight Loss Market with New Launch

1d agoNASDAQ.COM

Eli Lilly's Innovation Drives Long-Term Growth

1d agoFool

Kailera Therapeutics IPO Soars 62.5% on Nasdaq Debut

1d agoNewsfilter

Eli Lilly's Tirzepatide Shows Superior Weight Loss Effects Compared to Semaglutide

1d agoseekingalpha

Novo Nordisk and Eli Lilly Prescription Comparison

1d agostocktwits

Eli Lilly's Weight-Loss Drug Off to Slow Start in U.S. Market

2d agoYahoo Finance

Eli Lilly's Foundayo Prescriptions Surge Post Launch

2d agoseekingalpha

Viking Therapeutics: A Potential Obesity Market Leader

2d agoFool

Viking Therapeutics Targets Billion-Dollar Obesity Market

2d agoNASDAQ.COM

Three Biotech Companies Worth Watching

2d agoNASDAQ.COM

Three Biotech Stocks Worth Watching

2d agoFool

CNBC Investing Club April Meeting Highlights

2d agoCNBC